Novel Data‐Mining Methodologies for Adverse Drug Event Discovery and Analysis

An important goal of the health system is to identify new adverse drug events (ADEs) in the postapproval period. Data‐mining methods that can transform data into meaningful knowledge to inform patient safety have proven essential for this purpose. New opportunities have emerged to harness data sources that have not been used within the traditional framework. This article provides an overview of recent methodological innovations and data sources used to support ADE discovery and analysis.

[1]  D. Classen,et al.  Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. , 1997, JAMA.

[2]  Patrick B. Ryan,et al.  Health Outcomes of Interest in Observational Data: Issues in Identifying Definitions in the Literature , 2012 .

[3]  A. Borobia,et al.  A Pharmacovigilance Program From Laboratory Signals for the Detection and Reporting of Serious Adverse Drug Reactions in Hospitalized Patients , 2010, Clinical pharmacology and therapeutics.

[4]  Sebastian Schneeweiss,et al.  A basic study design for expedited safety signal evaluation based on electronic healthcare data , 2010, Pharmacoepidemiology and drug safety.

[5]  L. Meskin.  Proceed with caution. , 1998, Journal of the American Dental Association.

[6]  Ben Y. Reis,et al.  Predicting Adverse Drug Events Using Pharmacological Network Models , 2011, Science Translational Medicine.

[7]  Siddhartha R. Dalal,et al.  Using information mining of the medical literature to improve drug safety , 2011, J. Am. Medical Informatics Assoc..

[8]  R. O’Neill,et al.  Use of Screening Algorithms and Computer Systems to Efficiently Signal Higher-Than-Expected Combinations of Drugs and Events in the US FDA’s Spontaneous Reports Database , 2002, Drug safety.

[9]  W. DuMouchel,et al.  Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post‐marketing setting , 2003, Pharmacoepidemiology and drug safety.

[10]  Shawn E. Simpson.  Self-controlled methods for postmarketing drug safety surveillance in large-scale longitudinal data , 2011 .

[11]  Naomi L Kruhlak,et al.  Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part B. Use of (Q)SAR systems for early detection of drug-induced hepatobiliary and urinary tract toxicities. , 2009, Regulatory toxicology and pharmacology : RTP.

[12]  A Bate,et al.  Decision support methods for the detection of adverse events in post-marketing data. , 2009, Drug discovery today.

[13]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[14]  David Madigan,et al.  Large‐scale regression‐based pattern discovery: The example of screening the WHO global drug safety database , 2010, Stat. Anal. Data Min..

[15]  M Alan Brookhart,et al.  The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration , 2011, Pharmacoepidemiology and drug safety.

[16]  A. Butte,et al.  Predicting Adverse Drug Reactions Using Publicly Available PubChem BioAssay Data , 2011, Clinical pharmacology and therapeutics.

[17]  R. Platt,et al.  The new Sentinel Network--improving the evidence of medical-product safety. , 2009, The New England journal of medicine.

[18]  Johan Hopstadius,et al.  Safety surveillance of longitudinal databases: methodological considerations , 2011, Pharmacoepidemiology and drug safety.

[19]  M. Massagli,et al.  Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm , 2011, Nature Biotechnology.

[20]  David Madigan,et al.  Disproportionality methods for pharmacovigilance in longitudinal observational databases , 2013, Statistical methods in medical research.

[21]  M. Hauben,et al.  Data mining for signals in spontaneous reporting databases: proceed with caution , 2007, Pharmacoepidemiology and drug safety.

[22]  W. DuMouchel,et al.  Novel Statistical Tools for Monitoring the Safety of Marketed Drugs , 2007, Clinical pharmacology and therapeutics.

[23]  Scott M Berry,et al.  Accounting for Multiplicities in Assessing Drug Safety: A Three‐Level Hierarchical Mixture Model , 2004, Biometrics.

[24]  M. Schuemie,et al.  Combining electronic healthcare databases in Europe to allow for large‐scale drug safety monitoring: the EU‐ADR Project , 2011, Pharmacoepidemiology and drug safety.

[25]  M. Kulldorff,et al.  Early detection of adverse drug events within population‐based health networks: application of sequential testing methods , 2007, Pharmacoepidemiology and drug safety.

[26]  Prakash M. Nadkarni,et al.  Overcoming barriers to NLP for clinical text: the role of shared tasks and the need for additional creative solutions , 2011, J. Am. Medical Informatics Assoc..

[27]  Carol Friedman,et al.  Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis , 2011, J. Am. Medical Informatics Assoc..

[28]  Bruce W. Dearstyne,et al.  Methodological considerations , 1989 .

[29]  L. Becquemont,et al.  Pharmacogenomics of adverse drug reactions: practical applications and perspectives. , 2009, Pharmacogenomics.

[30]  R. Altman,et al.  Detecting Drug Interactions From Adverse‐Event Reports: Interaction Between Paroxetine and Pravastatin Increases Blood Glucose Levels , 2011, Clinical pharmacology and therapeutics.

[31]  Martijn J Schuemie,et al.  Methods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD , 2011, Pharmacoepidemiology and drug safety.

[32]  Mph Dr. Syed Rizwanuddin Ahmad MD.  Adverse drug event monitoring at the food and drug administration , 2007, Journal of General Internal Medicine.

[33]  S. Shoor,et al.  Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study , 2005, The Lancet.

[34]  Kenneth D. Mandl,et al.  The Tell-Tale Heart: Population-Based Surveillance Reveals an Association of Rofecoxib and Celecoxib with Myocardial Infarction , 2007, PloS one.

[35]  Enrique F Schisterman,et al.  The use and misuse of matching in case-control studies: the example of polycystic ovary syndrome. , 2007, Fertility and sterility.

[36]  Jian Yang,et al.  Towards Internet-Age Pharmacovigilance: Extracting Adverse Drug Reactions from User Posts in Health-Related Social Networks , 2010, BioNLP@ACL.

[37]  R Ball,et al.  Can Network Analysis Improve Pattern Recognition Among Adverse Events Following Immunization Reported to VAERS? , 2011, Clinical pharmacology and therapeutics.

[38]  Ralph B D'Agostino,et al.  Estimating treatment effects using observational data. , 2007, JAMA.

[39]  Cédrick Fairon,et al.  Annotation analysis for testing drug safety signals using unstructured clinical notes , 2012, J. Biomed. Semant..

[40]  David Madigan,et al.  An Evaluation of Three Signal-Detection Algorithms Using a Highly Inclusive Reference Event Database , 2009, Drug safety.

[41]  D. Madigan,et al.  The role of data mining in pharmacovigilance , 2005, Expert opinion on drug safety.

[42]  William DuMouchel,et al.  Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System , 1999 .

[43]  J. Avorn,et al.  A review of uses of health care utilization databases for epidemiologic research on therapeutics. , 2005, Journal of clinical epidemiology.

[44]  A. Chiang,et al.  Data‐Driven Methods to Discover Molecular Determinants of Serious Adverse Drug Events , 2009, Clinical pharmacology and therapeutics.

[45]  A. Persidis,et al.  Drug repurposing and adverse event prediction using high‐throughput literature analysis , 2011, Wiley interdisciplinary reviews. Systems biology and medicine.

[46]  Z. Anusz.  [Statistics in epidemiology]. , 1974, Pielegniarka i polozna.

[47]  J. Avorn,et al.  High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data , 2009, Epidemiology.

[48]  Christopher G. Chute,et al.  The National Center for Biomedical Ontology , 2012, J. Am. Medical Informatics Assoc..

[49]  Malcolm Maclure,et al.  Design considerations in an active medical product safety monitoring system , 2012, Pharmacoepidemiology and drug safety.

[50]  D. Graham,et al.  Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase-2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study , 2005 .

[51]  Carol Friedman,et al.  Mining multi-item drug adverse effect associations in spontaneous reporting systems , 2010, BMC Bioinformatics.

[52]  J. Overhage,et al.  Advancing the Science for Active Surveillance: Rationale and Design for the Observational Medical Outcomes Partnership , 2010, Annals of Internal Medicine.

[53]  A. Bate,et al.  A Bayesian neural network method for adverse drug reaction signal generation , 1998, European Journal of Clinical Pharmacology.

[54]  R. Glen,et al.  Molecular similarity: a key technique in molecular informatics. , 2004, Organic & biomolecular chemistry.

[55]  E. Matthews,et al.  Prediction of drug-related cardiac adverse effects in humans--B: use of QSAR programs for early detection of drug-induced cardiac toxicities. , 2010, Regulatory toxicology and pharmacology : RTP.

[56]  Gaurav Deshpande,et al.  Data Mining in Drug Safety , 2010, Pharmaceutical Medicine.

[57]  Sebastian Schneeweiss,et al.  Managing drug-risk information--what to do with all those new numbers. , 2009, The New England journal of medicine.

[58]  D. Wysowski,et al.  Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. , 2005, Archives of internal medicine.

[59]  Richard Solomon,et al.  Contrast Media and Nephropathy: Findings From Systematic Analysis and Food and Drug Administration Reports of Adverse Effects , 2006, Investigative radiology.

[60]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[61]  David Madigan,et al.  Large-Scale Bayesian Logistic Regression for Text Categorization , 2007, Technometrics.

[62]  J. Rassen,et al.  Confounding Control in Healthcare Database Research: Challenges and Potential Approaches , 2010, Medical care.

[63]  M. Haack.  Part B , 1942 .

[64]  A. Bate,et al.  Quantitative signal detection using spontaneous ADR reporting , 2009, Pharmacoepidemiology and drug safety.

[65]  Petko Valtchev,et al.  Mining Safety Signals in Spontaneous Reports Database Using Concept Analysis , 2009, AIME.

[66]  Mark McClellan,et al.  Drug safety reform at the FDA--pendulum swing or systematic improvement? , 2007, The New England journal of medicine.

[67]  G Hripcsak,et al.  Biclustering of Adverse Drug Events in the FDA's Spontaneous Reporting System , 2011, Clinical pharmacology and therapeutics.

[68]  Bo Peng,et al.  High-Performance Signal Detection for Adverse Drug Events using MapReduce Paradigm. , 2010, AMIA ... Annual Symposium proceedings. AMIA Symposium.

[69]  Robert D Gibbons,et al.  Post-approval drug safety surveillance. , 2010, Annual review of public health.

[70]  Tomasz Imielinski,et al.  Mining association rules between sets of items in large databases , 1993, SIGMOD Conference.